Vertex Pharma Stock Surges After FDA Approves Non-Opioid Pain Drug
Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.
Monthly Prescribing Reference3 時間
Journavx, a Nonopioid Oral Pain Medication, Gets FDA Approval
The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to severe acute pain in adults.
Washington Square News6 時間
Student gov’t opens elections to entire student body
NYU’s Student Government Assembly will allow all students to vote in its chair elections, a process reserved for SGA ...
ResMed Inc. (NYSE:RMD) Q2 2025 Earnings Call Transcript
Q2 2025 Earnings Call Transcript January 30, 2025 ResMed Inc. beats earnings expectations. Reported EPS is $2.43, expectations were $2.32. Operator: Welcome to the Q2 Fiscal Year 2025 ResMed Earnings ...
Q2 2025 Resmed Inc Earnings Call
Welcome to the Q2 fiscal-year 2025 ResMed earnings conference call. My name is Matt and I'll be your operator for today's call. (Operator Instructions) Please note that this conference call is being ...
ResMed: Digital Health Drives Q2 Growth
ResMed reported robust earnings for the second quarter of fiscal 2025, surpassing expectations and showcasing strong growth ...